Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $20.22, for a total transaction of $4,044,000.00. Following the sale, the chief executive officer directly owned 1,504,959 shares in the company, valued at approximately $30,430,270.98. The trade was a 11.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Eric Venker also recently made the following trade(s):

• On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The shares were sold at an average price of $17.06, for a total value of $2,020,211.08.
• On Wednesday, October 15th, Eric Venker sold 414,683 shares of Roivant Sciences stock. The shares were sold at an average price of $16.93, for a total value of $7,020,583.19.
• On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The stock was sold at an average price of $17.05, for a total value of $5,426,708.10.
• On Monday, October 13th, Eric Venker sold 20,727 shares of Roivant Sciences stock. The shares were sold at an average price of $16.25, for a total transaction of $336,813.75.
• On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The shares were sold at an average price of $16.30, for a total transaction of $1,710,522.00.
• On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The stock was sold at an average price of $16.20, for a total value of $2,245,352.40.
• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The stock was sold at an average price of $16.34, for a total value of $2,800,610.64.
• On Tuesday, October 7th, Eric Venker sold 355,161 shares of Roivant Sciences stock. The shares were sold at an average price of $16.15, for a total value of $5,735,850.15.
• On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The stock was sold at an average price of $14.83, for a total transaction of $9,061,130.00.
• On Monday, September 22nd, Eric Venker sold 416,182 shares of Roivant Sciences stock. The shares were sold at an average price of $14.99, for a total transaction of $6,238,568.18.

Roivant Sciences Stock Up 0.2%

ROIV traded up $0.05 during trading on Friday, reaching $20.62. The company’s stock had a trading volume of 9,415,298 shares, compared to its average volume of 8,659,502. The firm has a fifty day simple moving average of $16.16 and a two-hundred day simple moving average of $12.99. The company has a market cap of $14.08 billion, a price-to-earnings ratio of -29.46 and a beta of 1.23. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $20.77.

Analyst Ratings Changes

A number of analysts have issued reports on ROIV shares. Citigroup raised their target price on Roivant Sciences from $16.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Jefferies Financial Group raised their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. The Goldman Sachs Group increased their price target on shares of Roivant Sciences from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Guggenheim upped their price objective on Roivant Sciences from $15.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Finally, Bank of America raised their price objective on Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $21.06.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in ROIV. CenterBook Partners LP increased its stake in Roivant Sciences by 147.5% in the 3rd quarter. CenterBook Partners LP now owns 247,443 shares of the company’s stock valued at $3,744,000 after buying an additional 147,453 shares during the period. State of New Jersey Common Pension Fund D grew its holdings in shares of Roivant Sciences by 4.6% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 180,107 shares of the company’s stock worth $2,725,000 after acquiring an additional 7,946 shares during the period. Candriam S.C.A. raised its stake in shares of Roivant Sciences by 43.5% during the 3rd quarter. Candriam S.C.A. now owns 2,157,995 shares of the company’s stock worth $32,650,000 after buying an additional 654,001 shares during the last quarter. State of Michigan Retirement System lifted its holdings in shares of Roivant Sciences by 1.2% in the third quarter. State of Michigan Retirement System now owns 102,400 shares of the company’s stock valued at $1,549,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Bessemer Group Inc. grew its holdings in Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.